Strong Consolidated Results and Raised Guidance
Total revenues of $68.5 billion and adjusted EPS of $7.79 in Q1 2026 (16% year-over-year EPS growth). Company raised full-year 2026 adjusted EPS outlook to at least $30.35.
Evernorth Revenue Growth
Evernorth revenues grew 9% year-over-year to $58.4 billion in Q1 2026 with pretax adjusted earnings of $1.5 billion (slightly ahead of expectations).
Specialty & Care Services Momentum
Specialty and Care Services pretax adjusted earnings increased 20% year-over-year to $1.1 billion, driven by strong volume growth, biosimilar and specialty generic adoption, and contribution from the Shields Health Solutions investment.
Cigna Healthcare Outperformance
Cigna Healthcare pretax adjusted earnings were $1.5 billion with revenues of $11.5 billion; earnings grew 18% year-over-year. First-quarter medical care ratio (MCR) was 79.8%, favorable to expectations.
Progress on Prior Authorization and Customer Experience
Removed hundreds of tests/procedures from prior authorization in the U.S., decreasing medical prior authorization volume by ~15%. Cigna Healthcare ranked #1 by J.D. Power in digital experience satisfaction for commercial members for the second consecutive year.
Innovation: Rebate-Free Pharmacy Model and AI
Announced the transformative rebate-free pharmacy service model ("Signature") projected to deliver brand drug prices ~30% lower with full transparency; PBS selling season shows strong early market interest. Company is leveraging data and AI across businesses (e.g., predictive high-cost claimant model driving ~$2,000 per engaged member per year in savings).
Operational Efficiency and Digital Adoption
Digital and AI-enabled improvements contributed to a 20% reduction in inbound calls for digitally eligible Cigna Healthcare U.S. employer customers and a 25% reduction in inbound calls for PBS members versus two years ago.
Capital and Balance Sheet Discipline
Operating cash flow of $1.1 billion in Q1, debt-to-capitalization ratio improved to 42.3% (70 bps improvement vs. year-end 2025) and expected to be lower by year-end 2026; company reiterated capital allocation balance including reinvestment, dividends and share repurchases.